Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 379

1.

Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer.

Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Singh G.

Nucl Med Commun. 2013 Jun;34(6):557-61. doi: 10.1097/MNM.0b013e328360d910.

PMID:
23549551
2.

Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.

Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.

Nucl Med Commun. 2012 Jun;33(6):591-6. doi: 10.1097/MNM.0b013e3283516716.

PMID:
22334135
3.

The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.

Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G.

Hell J Nucl Med. 2011 May-Aug;14(2):135-9.

PMID:
21761015
4.

18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.

Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espié M.

J Nucl Med. 2013 Jan;54(1):5-11. doi: 10.2967/jnumed.112.106864. Epub 2012 Dec 4.

5.

Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.

Ng SP, David S, Alamgeer M, Ganju V.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):111-7. doi: 10.1016/j.ijrobp.2015.05.012. Epub 2015 May 15.

PMID:
26279029
6.

Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G, Heusner TA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):852-63. doi: 10.1007/s00259-012-2077-0. Epub 2012 Mar 6.

PMID:
22392069
7.

18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.

van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, Meijer S, van der Wall E, Buter J, Pinedo HM, Teule GJ, Lammertsma AA.

J Clin Oncol. 2004 Apr 1;22(7):1253-9.

PMID:
15051773
8.

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.

Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast Cancer Res Treat. 2012 Jan;131(1):117-26. doi: 10.1007/s10549-011-1767-9. Epub 2011 Sep 21.

PMID:
21935602
9.

The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients.

Sen F, Akpinar AT, Ogur U, Duman G, Tamgac F, Alper E.

Nucl Med Commun. 2013 Jun;34(6):571-6. doi: 10.1097/MNM.0b013e328360d8ec.

PMID:
23549550
10.

FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.

Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT.

Oncologist. 2011;16(8):1111-9. doi: 10.1634/theoncologist.2011-0089. Epub 2011 Jul 17.

11.
12.
13.

Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.

Purandare NC, Pramesh CS, Karimundackal G, Jiwnani S, Agrawal A, Shah S, Kulkarni M, Laskar SG, Rangarajan V.

Nucl Med Commun. 2014 Aug;35(8):864-9. doi: 10.1097/MNM.0000000000000137.

PMID:
24751701
15.

¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.

Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL.

Eur J Radiol. 2014 Oct;83(10):1925-33. doi: 10.1016/j.ejrad.2014.05.037. Epub 2014 Jun 17.

PMID:
24985086
16.

Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.

Sharma P, Jain TK, Singh H, Suman SK, Faizi NA, Kumar R, Bal C, Malhotra A, Kumar R.

Nucl Med Commun. 2013 Mar;34(3):211-9. doi: 10.1097/MNM.0b013e32835bc4c4.

PMID:
23353886
17.

High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.

Picchio M, Mangili G, Samanes Gajate AM, De Marzi P, Spinapolice EG, Mapelli P, Giovacchini G, Sigismondi C, Viganò R, Sironi S, Messa C.

Nucl Med Commun. 2010 Jun;31(6):506-12. doi: 10.1097/MNM.0b013e328337cb47.

PMID:
20168262
18.

Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, Weber WA, Ulaner GA.

J Nucl Med. 2014 Oct;55(10):1578-83. doi: 10.2967/jnumed.114.143297. Epub 2014 Sep 11.

19.

Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):377-85. doi: 10.1007/s00259-014-2941-1. Epub 2014 Nov 29.

PMID:
25432784
20.

Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.

Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, Koretz K, Glatting G, Rieber A, Kreienberg R, Buck AC, Reske SN.

Eur J Nucl Med. 2001 Mar;28(3):351-8.

PMID:
11315604

Supplemental Content

Support Center